ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2555

The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra

Karel Pavelka1, Jakub Zavada2, Marketa Fojtikova3, Sarka Forejtova4 and Karel Hejduk5, 1Institute of Rheumatology, Prague, Czech Republic, 2Charles University, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Rheumatology, Institute of Rheumatology, Prague, Czech Republic, 5Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and anti-TNF therapy, DMARDs

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established.

Methods: Main goal of this study was to compare the probability of achieving low disease activity (LDA) while persisting on adalimumab (ADA) therapy in AS patients treated by either ADA alone, or by combination of ADA + csDMARDs.  This analysis was conducted within the national biologics registry with mandatory registration for all patients with AS who start treatment with biologics.  All patients with AS treated with ADA as a first line anti-TNF drug with available baseline BASDAI and CRP were included in the analysis. To get reimbursement for anti-TNF therapy, all AS patients had to have high baseline disease activity (defined as BASDAI >4, and CRP > 10 mg/l). LDA was defined as BASDAI < 4 and CRP <5 mg/l. Pre-specifed sensitivity analyses were conducted in patients with pure axial, and combined axial+peripheral forms of AS.

Results: Data for 481 patients were available for the analysis (table). There was no difference in the primary outcome either in the total cohort (figure 1), or in the subset of patients with combined axial and peripheral involvement. In patients with pure axial form of AS, higher probability of achieving  LDA while persisting on ADA therapy was observed in some, but not all time-points of follow-up (figure 2). Patients on co-therapy with methotrexate (n=55) fared similarly as those on sulfasalazine (n=141).

Conclusion: Co-therapy with csDMARDs did not increase the overall probability of reaching LDA and drug survival on ADA in AS patients.

Acknowledgements: This work was supported by project of MHCR for conceptual development of research organization 023728.

Table 1 – baseline characteristics

ADA monotherapy

(N=259)

ADA+ csDMARD

(N=222)

p-value

Female  (%)

24.3

33.3

0.029

Age (years)

39 (10)

39 (11)

0.513

Disease duration  (years)

9,6 (9,4)

7,7 (7,6)

0.088

Pure axial form n(%)

118 (45.6%)

75 (33.8)

0.009

Axial and  peripheral form n(%)

141 (54.4%)

147 (66.2)

CRP (mg/l)

23,2 (20,2)

28,2 (26,7)

0.111

BASDAI

6,1 (1,7)

6,3 (1,8)

0.160

HAQ

1,1 (0,5)

1,1 (0,5)

0.692

Data are mean (SD) if not stated otherwise

Figure 1

Figure 2


Disclosure:

K. Pavelka,
None;

J. Zavada,
None;

M. Fojtikova,
None;

S. Forejtova,
None;

K. Hejduk,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-co-medication-with-conventional-synthetic-csdmards-on-achieving-low-disease-activity-while-persisting-on-adalimumab-therapy-in-patients-with-ankylosing-spondylitis-axial-spondylarthri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.